Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Carclo Plc LSE:CAR London Ordinary Share GB0001751915 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.70 3.14% 23.00 22.50 23.20 23.20 22.20 22.20 364,630 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 110.5 -0.5 -15.5 - 17

Carclo Share Discussion Threads

Showing 17801 to 17823 of 18650 messages
Chat Pages: Latest  722  721  720  719  718  717  716  715  714  713  712  711  Older
DateSubjectAuthorDiscuss
18/9/2018
15:12
Queeny2, given the AGM was so much earlier this year, perhaps we'll get an H1 trading update at some point at the end of this month/early October. As for VR315, CAR and VEC initially developed the Gyrophaler device together: Https://www.investegate.co.uk/article.aspx?id=200412060700100322G This is used in the AirFluSal® Forspiro® product marketed by Sandoz - formerly known as VR315: Https://aerosol-soc.com/abstracts/overview-design-verification-testing-process-gyrohaler-dry-powder-inhaler/
rivaldo
12/9/2018
22:29
Jordan-based drugmaker Hikma acquired the VR315 product when it bought Roxane Laboratories, with whom Vectura, a UK-based developer of inhaled therapies, had been partnerning in developing the product. - hxxps://www.thepharmaletter.com/article/vectura-and-hikma-s-generic-of-gsk-s-asthma-drug-advair-diskus-accepted-for-filing-by-us-fda
gordongekko4
12/9/2018
22:23
Rivaldo, please share your source regarding partnership between Carclo and Vectura re VR315
gordongekko4
12/9/2018
11:33
Next formal announcement 13 Nov half year results, that's a biggie this time round what with one thing and another. Do we expect a trading update or statement before then? Didn't have anything last year between AGM (which was early Sep) and interims so no reason to expect anything? One can wheel-spin like anything wondering if it's Axxion who have held the price up, where would it be without them, or whether it's just where it should be roughly and there's a news vacuum.
queeny2
12/9/2018
10:22
For the record, VEC announced news in their results yesterday re VR315 (for which CAR are partnered with them) that per N+1 Singer it's: "on track to submit data from the clinical endpoint study requested by the FDA in 2019." They assume "a peak sales potential of $230m post expected launch in 2020".
rivaldo
29/8/2018
22:57
Indeed - Axxion have bought another 720,000 shares in the last 3 weeks and now have 5.15m: Https://www.investegate.co.uk/carclo-plc--car-/rns/holding-s--in-company/201808291708391885Z/
rivaldo
29/8/2018
21:29
axxion keep buying now over 7%
9degrees
24/8/2018
18:53
One piece of negative news will send this tumbling, as track record of delivery and investor confidence are not positive. One piece of positive news will not cause a comparable jump in price, given lack of confidence. To rebuild that confidence will take a series of good news items. So for me this is a time to stand and watch ...especially after already having made 25% on this share when in the 120-160 range, and then baled before the fall. Nice to time one right :-)
bigtbigt
24/8/2018
13:26
Only a month ago the AGM statement read rather well, so backing CAR now is rather better than "blind": "Trading to date in the current financial year has been in line with the Board's expectations. Progress in securing new Automotive lighting and medical development contracts within LED Technologies and Technical Plastics has been good and is in line with our planned timescales. The implementation of our operational improvement plans is well underway and encouraging progress has been made."
rivaldo
24/8/2018
13:22
Here's a foolish forecast of events for the next 12 months: New chairman isn't there for show. Strategic review (already flagged) of the two core businesses, decision made to keep both. Main reason that the company would be even tinier if it didn't, and having two unconnected businesses does provide some kind of safety against mishaps in either one. Stated reason good prospects in both. CEO given a year to fix CTP after which he is replaced. Shares suffer another downleg as some hit to profits from the takeover process and some exceptionals resulting from strategic review, in an environment where they haven't yet regained any meaningful shareholder support, where market a bit worried about what Consort found that sent them running. I'd PROBABLY rather pay 110p in a year's time than 90p now when all of that has passed and clarity has emerged. Not unreasonable to say that they are terribly cheap now and you want to back the new management of Chair and FD, but it is blind at the moment. And the prospect of a dividend would work wonders imho.
queeny2
24/8/2018
09:41
Just for those with long memories: I still use my HP Omni 10 and following installation of Windows 10 it zips along.
backwoodsman
23/8/2018
09:50
We are where we were before the bid, with two 'negatives' and one 'positive' Positive - someone thought the company was worth well north of current share price Negative 1 - they then decided it wasn't Negative 2 - management spent several weeks with eyes at least partially off the ball Where we were, to remind, is that the board were concerned that CTP's underlying steady state profitability was very low, the numbers were flattered by tooling contracts. And the FD was sacked. The upside rivaldo refers to lies in fixing that.
queeny2
23/8/2018
09:09
if they don't deliver, the board will be in the firing line
davemac3
14/8/2018
09:21
Good to see the newly appointed FD buying a maiden £20,000 purchase of shares at 96p - the FD usually earns by far the lowest of the executive directors, so it's a reasonable early show of confidence: Https://www.investegate.co.uk/carclo-plc--car-/rns/director-pdmr-shareholding/201808131139266232X/ The statement in the news I posted that CAR have "won significant new business in the healthcare, medical diagnostics and eyecare fields during 2017/18" tallies with the recent AGM statement and the improved outlook in the results. CAR now have to deliver. If they do, there's lots of upside here. If not, the share price will continue to languish. The FD's share purchase is another small promising indicator.
rivaldo
13/8/2018
13:52
I’m not sure a maiden purchase on that scale counts as a positive sign at all..£20k falls firmly into ‘token gesture’ territory given her likely pay package..but at least it wasn’t a sell..
rhomboid
13/8/2018
12:56
Regarding more new significant business won by Carclo... Are we still not waiting to see the award of the last new significant business. Is the failure of this to come to fruition not the reason for the profit warnings? The only new news is Carclo are going to a Tradeshow the rest is old news and fluff.
prime investor
13/8/2018
12:41
The group Finance Director buys 20.45k shares, is she insane!
ansc
13/8/2018
10:52
News - this extract sounds reassuring: "Carclo has won significant new business in the healthcare, medical diagnostics and eyecare fields during 2017/18" Http://www.carclo-ctp.co.uk/media-centre/press-releases/25-07-2018.aspx "Carclo announces Compamed attendance 25 Jul 2018 London (UK), 25 July 2018: Carclo Technical Plastics announces that it will be exhibiting at the Compamed exhibition in Dusseldorf, Germany, 12-15 November 2018, on stand no 8AS19. Carclo has recently expanded its medical operations in its US, UK, Czech Republic, China and India facilities as it continues its strategy of increasing its contract manufacturing business globally. Underpinned by its EN13485 accreditation, Carclo has won significant new business in the healthcare, medical diagnostics and eyecare fields during 2017/18. Commenting, Divisional Chief Executive Officer Robert Stutzman stated “Carclo Technical Plastics has aggressive plans to continue developing our medical business, supported by Carclo’s engineering skills, global footprint and financial stability. Compamed, co-located with the renowned Medica tradeshow, is one of our prime marketing activities and we invite all customers and prospective customers to meet with us during the week.” Carclo’s clients range from globally-located divisions of major healthcare corporations to start-up companies who are developing products for the innovative yet highly-regulated medical industry. Products include medical and surgical disposables, drug delivery devices, reagent packs and diagnostic devices and ophthalmic equipment and consumables. Carclo Technical Plastics currently has manufacturing facilities in Eastern and Western USA; London, UK; Brno, Czech Republic; Shanghai, China, and Bangalore, India. The business increasingly adds value to its customers by assembling and packaging finished devices for the medical sector."
rivaldo
10/8/2018
12:45
1gw agree again. And they have some handy losses to use up :)The new chairman should indeed bring some focus coupled with the crash course in valuation. Senior I assume was diversified but whether to the zero synergy extent of little sub scale Carclo I don't know.
queeny2
10/8/2018
08:37
Axxion continue to buy per yesterday's RNS - now up to 4.66m shares: Http://uk.advfn.com/stock-market/london/carclo-CAR/share-news/Axxion-S-A-Form-8-3-Carclo-plc/78039218
rivaldo
09/8/2018
22:05
1gw:-I have now had a look at p21 Thanks - - Initial reaction is that very similar boiler plate to many risk managment statements from other companies with international business - CAR specific points have been slotted in - 1/3rd of UK situs revenue could be at risk from Brexit but no indication as to whether this is at risk from tariffs or quality certification. Again while 2/3rds of UK revenue is from the UK no idication as to what proportion of their coustomers revenue could be at risk and hence a knock-on risk- Overall impression of the risk statement is that it is very much a box ticking exercise - all risk factors covered but shareholders rather left in the dark in terms of quantification. I suspect the Board are as much in the dark as most economists, politicians and even the Bank of England !!- Conclusion - Would not pay more for stock that a p/e of 8 to 9 - Possibly less given the pension liabilities.
pugugly
09/8/2018
20:07
One thing the Consort experience should have done is give the board a much better insight into how their competitors/peers view and value Carclo. This should include a reasonable understanding now of how a CTP competitor/peer would assess Wipac, and perhaps also how a Wipac competitor/peer might assess Wipac (assuming they did sound out one or two, or at least got their advisors to do some serious analysis on the subject). I wonder if the board might now push the executive to re-examine the logic for keeping Wipac and CTP together (if there is any beyond having a bigger business to run). Would shareholders ultimately be better served by splitting the businesses as this would make it easier to achieve fair value for each one? Either spin off one if the two are viable as independent businesses or simply run a sale process for the smaller one - especially if they have already kicked off some work on this as part of the defence preparations.
1gw
09/8/2018
19:55
Carclo's own spin on the issue (Political uncertainty including Brexit) is on page 21 of the AR.
1gw
Chat Pages: Latest  722  721  720  719  718  717  716  715  714  713  712  711  Older
ADVFN Advertorial
Your Recent History
LSE
CAR
Carclo
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200930 19:37:17